drugset / Trial / NCT06138028

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

NCT06138028

Phase 2/3 Recruiting 90 enrolled Qingdao Central Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of treatment naive advanced esophageal squamous cell carcinoma patients. The purpose of this study was to evaluate the efficacy and safety of immunotherapy combined with chemotherapy and residual lesions irradiation of esophageal squamous cell carcinoma.

Timeline

Start
2023-09-20
Primary completion
2025-10-31
Completion
2026-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified
Subject Sintilimab Monoclonal antibody
Subject Tocetaxel Unknown